Patent 9290573 was granted and assigned to Novartis on March, 2016 by the United States Patent and Trademark Office.
The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.